R Dummer1, M Duvic2, J Scarisbrick3, E A Olsen4, S Rozati5, N Eggmann5, S M Goldinger5, K Hutchinson6, L Geskin7, T M Illidge8, E Giuliano9, J Elder10, Y H Kim11. 1. Department of Dermatology, University Hospital Zurich, Zurich, Switzerland reinhard.dummer@usz.ch. 2. Department of Dermatology, MD Anderson Cancer Center, Houston, USA. 3. Department Dermatology, Hospital Birmingham, Birmingham, UK. 4. Department of Dermatology, Duke University Medical Center, Durham, USA. 5. Department of Dermatology, University Hospital Zurich, Zurich, Switzerland. 6. Clinical Research, AMS Ltd, London, UK. 7. Department of Dermatology, University of Pittsburgh, Pittsburgh, USA. 8. School of Cancer and Imaging Sciences, University of Manchester, Manchester, UK. 9. Clinical Development, BioCryst Pharmaceuticals, Inc., Durham. 10. Statistics, PharPoint Research, Inc., Chapel Hill. 11. Clinical Research, Stanford Cancer Center, Stanford, USA.
Abstract
BACKGROUND: Forodesine is a potent inhibitor of purine nucleoside phosphorylase (PNP) that leads to intracellular accumulation of deoxyguanosine triphosphate (dGTP) in T and B cells, resulting in apoptosis. Forodesine has demonstrated impressive antitumor activity in early phase clinical trials in cutaneous T-cell lymphoma (CTCL). PATIENTS AND METHODS: In this phase II study, patients with CTCL who had already failed three or more systemic therapies were recruited. We investigated the response rate, safety and tolerability of oral forodesine treatment in subjects with cutaneous manifestations of CTCL, stages IB, IIA, IIB, III and IVA. The safety population encompassing all stages was used for analysis of accountability, demographics and safety. The efficacy population differed from the safety population by exclusion of stage IB and IIA patients. RESULTS: All 144 patients had performance status 0-2. The median duration of CTCL from diagnosis was 53 months (5-516 months). The median number of pretreatments was 4 (range: 3-15). No complete remissions were observed. In the efficacy group of patients, 11% achieved partial remission and 50% had stable disease. The median time to response was 56 days and the median duration of response was 191 days. A total of 96% of all treated patients reported one or more adverse events (AEs) and 33% reported a serious AE. The majority of AEs were classified as mild or moderate in severity. The most commonly reported AEs (>10%) were peripheral edema, fatigue, insomnia, pruritus, diarrhea, headache and nausea. Overall eight patients died during the study: five due to sepsis and infections, one due to a second malignancy (esophageal cancer), one due to disease progression and one due to liver failure. CONCLUSION: Oral forodesine at a dose of 200 mg daily is feasible and shows partial efficacy in this highly selected CTCL population and some durable responses.
BACKGROUND:Forodesine is a potent inhibitor of purine nucleoside phosphorylase (PNP) that leads to intracellular accumulation of deoxyguanosine triphosphate (dGTP) in T and B cells, resulting in apoptosis. Forodesine has demonstrated impressive antitumor activity in early phase clinical trials in cutaneous T-cell lymphoma (CTCL). PATIENTS AND METHODS: In this phase II study, patients with CTCL who had already failed three or more systemic therapies were recruited. We investigated the response rate, safety and tolerability of oral forodesine treatment in subjects with cutaneous manifestations of CTCL, stages IB, IIA, IIB, III and IVA. The safety population encompassing all stages was used for analysis of accountability, demographics and safety. The efficacy population differed from the safety population by exclusion of stage IB and IIApatients. RESULTS: All 144 patients had performance status 0-2. The median duration of CTCL from diagnosis was 53 months (5-516 months). The median number of pretreatments was 4 (range: 3-15). No complete remissions were observed. In the efficacy group of patients, 11% achieved partial remission and 50% had stable disease. The median time to response was 56 days and the median duration of response was 191 days. A total of 96% of all treated patients reported one or more adverse events (AEs) and 33% reported a serious AE. The majority of AEs were classified as mild or moderate in severity. The most commonly reported AEs (>10%) were peripheral edema, fatigue, insomnia, pruritus, diarrhea, headache and nausea. Overall eight patients died during the study: five due to sepsis and infections, one due to a second malignancy (esophageal cancer), one due to disease progression and one due to liver failure. CONCLUSION: Oral forodesine at a dose of 200 mg daily is feasible and shows partial efficacy in this highly selected CTCL population and some durable responses.
Authors: Rajesh K Harijan; Ioanna Zoi; Dimitri Antoniou; Steven D Schwartz; Vern L Schramm Journal: Proc Natl Acad Sci U S A Date: 2018-06-18 Impact factor: 11.205
Authors: Rajesh K Harijan; Ioanna Zoi; Dimitri Antoniou; Steven D Schwartz; Vern L Schramm Journal: Proc Natl Acad Sci U S A Date: 2017-06-05 Impact factor: 11.205
Authors: Gary B Evans; Scott A Cameron; Andreas Luxenburger; Rong Guan; Javier Suarez; Keisha Thomas; Vern L Schramm; Peter C Tyler Journal: Bioorg Med Chem Date: 2015-07-30 Impact factor: 3.641
Authors: Jon Pey; Edurne San José-Eneriz; María Carmen Ochoa; Iñigo Apaolaza; Pedro de Atauri; Angel Rubio; Xabier Cendoya; Estíbaliz Miranda; Leire Garate; Marta Cascante; Arkaitz Carracedo; Xabier Agirre; Felipe Prosper; Francisco J Planes Journal: Sci Rep Date: 2017-10-30 Impact factor: 4.379
Authors: Tamara Davenne; Jenny Klintman; Sushma Sharma; Rachel E Rigby; Henry T W Blest; Chiara Cursi; Anne Bridgeman; Bernadeta Dadonaite; Kim De Keersmaecker; Peter Hillmen; Andrei Chabes; Anna Schuh; Jan Rehwinkel Journal: Cell Rep Date: 2020-05-12 Impact factor: 9.423
Authors: Elisangela Oliveira Freitas; Dirlei Nico; Marcus Vinícius Alves-Silva; Alexandre Morrot; Keith Clinch; Gary B Evans; Peter C Tyler; Vern L Schramm; Clarisa B Palatnik-de-Sousa Journal: PLoS Negl Trop Dis Date: 2015-12-23